CSWYF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CSWYF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
China Shineway Pharmaceutical Group Ltd CSWYF
China Shineway Pharmaceutical Group CSWYF 92 Days Payable is 158.08 as of Dec. 2025, which is 33% above its 10-year median of 118.96. GuruFocus rates CSWYF with a GF Score™ of 92/100 and a GF Value™ of $0.88. The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, China Shineway Pharmaceutical Group ranks better than 75.95% on this metric.
China Shineway Pharmaceutical Group's average Accounts Payable for the six months ended in Dec. 2025 was $50.4 Mil. China Shineway Pharmaceutical Group's Cost of Goods Sold for the six months ended in Dec. 2025 was $58.2 Mil. Hence, China Shineway Pharmaceutical Group's Days Payable for the six months ended in Dec. 2025 was 158.08.
The historical rank and industry rank for China Shineway Pharmaceutical Group's Days Payable or its related term are showing as below:
During the past 13 years, China Shineway Pharmaceutical Group's highest Days Payable was 173.50. The lowest was 87.02. And the median was 118.96.
China Shineway Pharmaceutical Group's Days Payable declined from Dec. 2024 (182.87) to Dec. 2025 (158.08). It may suggest that China Shineway Pharmaceutical Group accelerated paying its suppliers.
The historical data trend for China Shineway Pharmaceutical Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| China Shineway Pharmaceutical Group Annual Data | |||||||||||||||||||||
| Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | Dec25 | |||||||||||
| Days Payable | Get a 7-Day Free Trial |
|
|
87.24 | 100.77 | 130.24 | 173.05 | 153.24 | |||||||||||||
| China Shineway Pharmaceutical Group Semi-Annual Data | ||||||||||||||||||||
| Jun16 | Dec16 | Jun17 | Dec17 | Jun18 | Dec18 | Jun19 | Dec19 | Jun20 | Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | Jun24 | Dec24 | Jun25 | Dec25 | |
| Days Payable | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
150.56 | 169.06 | 182.87 | 154.06 | 158.08 | ||
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Days Payable distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
China Shineway Pharmaceutical Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
| Days Payable (A: Dec. 2025 ) | |||||||||
| = | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
| = | ( (Accounts Payable (A: Dec. 2024 ) | + | Accounts Payable (A: Dec. 2025 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2025 ) | * | Days in Period |
| = | ( (55.347 | + | 48.277) | / | 2 ) | / | 123.412 | * | 365 |
| = | 51.812 | / | 123.412 | * | 365 | ||||
| = | 153.24 |
China Shineway Pharmaceutical Group's Days Payable for the quarter that ended in Dec. 2025 is calculated as:
| Days Payable (Q: Dec. 2025 ) | |||||||||
| = | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
| = | ( (Accounts Payable (Q: Jun. 2025 ) | + | Accounts Payable (Q: Dec. 2025 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2025 ) | * | Days in Period |
| = | ( (52.598 | + | 48.277) | / | 2 ) | / | 58.229 | * | 365 / 2 |
| = | 50.4375 | / | 58.229 | * | 365 / 2 | ||||
| = | 158.08 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued. The current stock price of $1.00 is trading 14.1% above its estimated GF Value™ of $0.88.
Key valuation signals for CSWYF:
No single metric tells the full story. See the CSWYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.